Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/05/2021
• Auteurs : Salim Si-MohamedSara BoccaliniPierre-Antoine RodeschRiham DessoukyElias LahoudThomas BroussaudMonica SigovanDelphine GamondesPhilippe CoulonYoad YagilL. BousselPhilippe Douek
• Organismes : Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Hospices Civils de Lyon Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Hospices Civils de Lyon Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Zagazig University Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Hospices Civils de Lyon Philips Research Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Hospices Civils de Lyon Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé
• Publié dans Diagnostic and Interventional Imaging le 01/11/2020

---

Résumé : Purpose: The purpose of this study was to characterize the technical capabilities and feasibility of a large field-of-view clinical spectral photon-counting computed tomography (SPCCT) prototype for high-resolution (HR) lung imaging. Materials and methods: Measurement of modulation transfer function (MTF) and acquisition of a line pairs phantom were performed. An anthropomorphic lung nodule phantom was scanned with standard (120kVp, 62mAs), low (120kVp, 11mAs), and ultra-low (80kVp, 3mAs) radiation doses. A human volunteer underwent standard (120kVp, 63mAs) and low (120kVp, 11mAs) dose scans after approval by the ethics committee. HR images were reconstructed with 1024 matrix, 300mm field of view and 0.25mm slice thickness using a filtered-back projection (FBP) and two levels of iterative reconstruction (iDose 5 and 9). The conspicuity and sharpness of various lung structures (distal airways, vessels, fissures and proximal bronchial wall), image noise, and overall image quality were independently analyzed by three radiologists and compared to a previous HR lung CT examination of the same volunteer performed with a conventional CT equipped with energy integrating detectors (120kVp, 10mAs, FBP). Results: Ten percent MTF was measured at 22.3lp/cm with a cut-off at 31lp/cm. Up to 28lp/cm were depicted. While mixed and solid nodules were easily depicted on standard and low-dose phantom images, higher iDose levels and slice thicknesses (1mm) were needed to visualize ground-glass components on ultra-low-dose images. Standard dose SPCCT images of in vivo lung structures were of greater conspicuity and sharpness, with greater overall image quality, and similar image noise (despite a flux reduction of 23%) to conventional CT images. Low-dose SPCCT images were of greater or similar conspicuity and sharpness, similar overall image quality, and lower but acceptable image noise (despite a flux reduction of 89%). Conclusions: A large field-of-view SPCCT prototype demonstrates HR technical capabilities and high image quality for high resolution lung CT in human.

---

Fichiers liés : S2211568421000012.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/05/2021
• Auteurs : Philippe ColsonAnthony LevasseurJeremy DelerceLucile PinaultPierre DudouetChristian DevauxPierre-Edouard FournierBernard La ScolaJean-Christophe LagierDidier Raoult
• Organismes : Microbes Evolution Phylogénie et Infections Institut Hospitalier Universitaire Méditerranée Infection Microbes Evolution Phylogénie et Infections Institut Hospitalier Universitaire Méditerranée Infection Microbes Evolution Phylogénie et Infections Institut Hospitalier Universitaire Méditerranée Infection Microbes Evolution Phylogénie et Infections Institut Hospitalier Universitaire Méditerranée Infection Institut Hospitalier Universitaire Méditerranée Infection Microbes Evolution Phylogénie et Infections Institut Hospitalier Universitaire Méditerranée Infection Centre National de la Recherche Scientifique Microbes Evolution Phylogénie et Infections Institut Hospitalier Universitaire Méditerranée Infection Microbes Evolution Phylogénie et Infections Institut Hospitalier Universitaire Méditerranée Infection Microbes Evolution Phylogénie et Infections Institut Hospitalier Universitaire Méditerranée Infection Microbes Evolution Phylogénie et Infections Institut Hospitalier Universitaire Méditerranée Infection
• Publié dans Clinical Microbiology and Infection le 30/10/2020

---

Fichiers liés : S1198743X21002263.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/05/2021
• Auteurs : Chloé BizotMarie-Anne BlinPierre GuichardJonathan HamonVincent FernandezPatrick SoudanJoël GaubicherPhilippe Poizot
• Organismes : Institut des Matériaux Jean Rouxel ARMOR SAS ARMOR SAS ARMOR SAS Institut des Matériaux Jean Rouxel Institut des Matériaux Jean Rouxel Institut des Matériaux Jean Rouxel Institut des Matériaux Jean Rouxel Institut des Matériaux Jean Rouxel
• Publié dans Electrochemistry Communications le 02/11/2020

---

Fichiers liés : 1-s2.0-S1388248121000977-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/05/2021
• Auteurs : Roxana AmélieCharles R.G. GuttmannJuan Carlos PrietoFabien RollotMiklos PalotaiSandra VukusicRomain MarignierFrançois CottonRené AnxionnatJean-Paul ArmspachBertrand AudoinChristian BarillotIsabelle BerryFabrice BonnevilleClaire BoutetGiovanni CastelnovoFrédéric CervenanskyMikael CohenOlivier CommowickJérôme de SèzeVincent DoussetFrançoise Durand-DubiefGilles EdanJean-Christophe FerréDamien GalanaudTristan GlatardSylvie GrandJustine GuillaumontRémy GuillevinSalem HannounFabrice HeitzAlexandre KrainikStéphane KremerPierre M LabaugeNicolas Menjot de ChampfleurJean‐philippe RanjevaJean-Amédée RochDominique Sappey-MarinierJulien SavatovskyBruno StankoffAyman TourbahThomas TourdiasBruno BrochetMichel ClanetNathalie DufayDavid-Axel LaplaudMarie-Claire MazeThibault MoreauCédric TrollietBernard FrangoulisJavier OlaizJean PelletierBertrand BourreDavid BrassatPhilippe CabreJean-Philippe CamdessanchéWilliam CamuOlivier CasezPierre ClavelouNicolas CollonguesAlain CreangeGilles DeferMarc DebouverieOlivier GoutChristine Lebrun-FrénayCatherine LubetzkiCaroline PapeixPatrick VermerschHélène Zéphir
• Organismes : Service de Radiologie [Hôpital Femme Mère Enfant - HCL] Department of Radiology [Boston] Department of Radiology [Boston] Observatoire Français de la Sclérose En Plaques [Lyon] Department of Radiology [Boston] Service de Neurologie [Lyon] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Imagerie Adaptative Diagnostique et Interventionnelle Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie Centre de résonance magnétique biologique et médicale Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - APHM] Neuroimagerie: méthodes et applications Service de Médecine Nucléaire - Pierre-Paul Riquet [CHU Toulouse] Pôle Neurosciences [CHU Toulouse] Service de Radiologie [CHU Saint-Etienne] CHU Pitié-Salpêtrière [AP-HP] Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Service de Neurologie [CHU Nice] Neuroimagerie: méthodes et applications Centre Hospitalier Universitaire [Strasbourg] Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Neuroimagerie: méthodes et applications Neuroimagerie: méthodes et applications CHU Pitié-Salpêtrière [AP-HP] Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Service de neuroradiologie [Grenoble] Neuroimagerie: méthodes et applications Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie Service de neuroradiologie [Grenoble] Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie Département de neurologie [Montpellier] Institut d’Imagerie Fonctionnelle Humaine [CHU Montpellier] Centre de résonance magnétique biologique et médicale Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - APHM] Hôpital privé Jean Mermoz [Lyon] Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé CHU Rothschild [AP-HP] CHU Tenon [AP-HP] Université de Reims Champagne-Ardenne Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale Service de neurologie [Bordeaux] Neurologie Vasculaire [Toulouse] Service de Neurologie [Lyon] Service de neurochirurgie [CHU Nantes] Service de Neurologie [Lyon] Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon) Observatoire Français de la Sclérose En Plaques [Lyon] Fondation Eugène Devic EDMUS Fondation Eugène Devic EDMUS Centre de résonance magnétique biologique et médicale Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - APHM] Hôpital Charles Nicolle [Rouen] Pôle Neurosciences [CHU Toulouse] Hôpital Albert Clarac [CHU de la Martinique] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Institut de Biologie Computationnelle Département de neurologie Service Neurologie [CHU Clermont-Ferrand] Hôpital de Hautepierre [Strasbourg] Département de neurosciences Service de Neurologie [CHU Caen] Service de neurologie [CHRU Nancy] CHU Rothschild [AP-HP] Service de Neurologie [CHU Nice] CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Département de neurologie [Lille] Département de neurologie [Lille]
• Publié dans Journal de Neuroradiologie / Journal of Neuroradiology le 26/10/2020

---

Résumé : Background and purposeTo determine the precise incidence of lesions at sites of high Aquaporin-4 expression (hAQP4) and their possible association with known neuromyelitis optica spectrum disease (NMOSD) lesions patterns.Materials and methodsA retrospective analysis of brain and, when available, spinal cord MRI scans of 54 NMOSD patients recruited among the French NMOSD cohort was performed. Brain lesions were annotated as MS-like, non-specific, or evocative of NMOSD. The topography of hAQP4 was reassessed by human brain atlas. The incidence of lesions in hAQP4 and their association with lesions evocative of NMOSD was estimated.ResultsAmong those included (41/54 female, mean age: 45 years) 47/54 (87%) presented brain lesions. Twenty-six/47 (55%) had lesions in hAQP4. Thirty-two/54 patients (60%) had lesions considered evocative of NMOSD. The majority of them also presented lesions in hAQP4 (65%, 21/32). Patients with lesions in hAQP4 and lesions evocative of NMOSD demonstrated more extensive myelitis compared to the other patients (7 [6–10] versus 4 [3–5] vertebral segments, P = 0.009).ConclusionThe coexistence of lesions evocative of NMOSD and in hAQP4 is associated with significantly more extensive myelitis, and might have pathophysiological and clinical significance.

---

Source

---

• Type de publi. :
• Date de publi. : 01/05/2021
• Auteurs : Garance CroquantDoriane AguannoA. PeyrottesLoïc BrotChristine BelloirLoïc BriandJean-Pierre GrillSophie ThenetLuisa de SordiPhilippe Seksik
• Organismes : Sorbonne Université École Pratique des Hautes Études École normale supérieure - Paris Sorbonne Université Centre des Sciences du Goût et de l'Alimentation [Dijon] Centre des Sciences du Goût et de l'Alimentation [Dijon] Sorbonne Université École Pratique des Hautes Études Centre de Recherche Saint-Antoine Sorbonne Université Sorbonne Université Centre de Recherche Saint-Antoine
• Publié dans Journal of Crohn's and Colitis le 31/10/2020

---

Résumé : Background Acyl-Homoserine Lactones (AHLs) are Quorum Sensing molecules involved in the communication network of bacteria and can also have an impact on the host’s cells. We recently showed, in the gut ecosystems, the presence AHLs and among them we identified one that has never been described: 3-oxo-C12:2. This molecule was decreased in Inflammatory Bowel Disease (IBD) patients, especially during flare, and its presence was correlated to normobiosis. Interestingly, 3-oxo-C12:2 is structurally close to an AHL well described and synthesized by P. aeruginosa, 3-oxo-C12. We intent to describe 3-oxo-C12:2 effects on gut inflammation and to identified which signalling pathways are involved. Given its analogous structure to 3-oxo-C12, we hypothesized that 3-oxo-C12:2 can interact with the same cellular partners, in particular a bitter taste receptor (BTR), called T2R138, which is a GPCR expressed by immune and epithelial gut cells. Methods To test our hypothesis, we used murine macrophages cell line RAW264.7, stimulated by interferon-ɣ (IFN-g, 20U/mL) and lipopolysaccharide (LPS, 10ng/mL). We performed a transcriptome analysis using RNAseq to identify inflammatory pathways involved in the effects. Inflammatory response was monitored by measuring cytokine secretion TFNα via ELISA. Probenecid, a known allosteric inhibitor for T2R138, was used to study T2R138 role in AHL signalling. BTR screening assay was performed to extend search for 3-oxo-C12:2 receptors. Cytotoxicity was measured via Lactate Dehydrogenase release. Results After LPS/IFN-γ activation, we observed a decrease of secreted TNFα when cells are exposed to 3-oxo-C12:2, in a dose dependent manner: 15μM (-30%, p<0.05), 25μM (-50%, p<0.001) et 50μM (-65%, p<0.0001), no change were observed in steady state. Itreflects an anti-inflammatory effect, without increasing cytotoxicity. To identify mechanisms behind those effects, we analysed the transcriptome of RAW264.7 cells exposed to AHL. JAK-STAT and NF-κB pathways were differentially down-regulated in presence of 3-oxo-C12:2. In addition, the anti-inflammatory effects were lost in presence of Probenecid, a T2R138 inhibitor. In a BTR screening assay, we confirmed that 3-oxo-C12:2 activates T2R38, but also five other BTR (T2R13, T2R8, T2R14, T2R1, T2R10). Conclusion 3-oxo-C12:2 exerts a dose dependent anti-inflammatory effect on murine immune cells. This response is partly mediated by the bitter taste receptor T2R138. This receptor is a potential target of our AHL of interest and we are currently studying the inflammatory pathways involved behind those effects. Studying the signalling between the receptor and the anti-inflammatory response would allow us to better understand the inter-kingdom dialogue between microbiota involving AHL in IBD.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/05/2021
• Auteurs : Manel AllegMorgane SolisSeyyid BalogluFrançois CottonPhilippe KerschenBertrand BourreGuido AhleJean-Pierre PruvoXavier LeclercPatrick VermerschCaroline PapeixÉlisabeth MaillartCaroline HouillierCécile Moluçon ChabrotBéatrice ClaiseSandra MalakGuillaume Martin-BlondelFabrice BonnevilleAlexis CaulierJean-Pierre MarolleauJérôme Tamburini BonnefoyPhilippe AgapeCéline KennelXavier RousselAdrien ChauchetJérôme de SèzeSamira Fafi-KremerStéphane Kremer
• Organismes : Hôpitaux Universitaires de Strasbourg Laboratoire de Virologie [Strasbourg] Hôpitaux Universitaires de Strasbourg Centre Hospitalier Lyon Sud [CHU - HCL] Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Centre Hospitalier de Luxembourg [Luxembourg] CHU Rouen Service de Neurologie [Hôpitaux Civils de Colmar] Lille Neurosciences & Cognition - U 1172 Lille Neurosciences & Cognition - U 1172 Lille Neurosciences & Cognition - U 1172 Departement de Neuroradiologie [Lille] CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] CHU Clermont-Ferrand CHU Clermont-Ferrand Institut Curie - Saint Cloud Service Maladies infectieuses et tropicales [CHU Toulouse] Centre de Physiopathologie Toulouse Purpan Service Neuroradiologie Diagnostique et Thérapeutique [CHU Toulouse] Laboratoire d'Hématologie [CHU Amiens] Laboratoire d'Hématologie [CHU Amiens] AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris] Institut de Cancérologie de l'Ouest [Angers/Nantes] CHU Limoges Centre Hospitalier Régional Universitaire de Besançon Centre Hospitalier Régional Universitaire de Besançon Hôpital de Hautepierre [Strasbourg] Laboratoire de Virologie [Strasbourg] Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie Hôpitaux Universitaires de Strasbourg
• Publié dans European Radiology le 23/10/2020

---

Résumé : Objectives: To compare brain MRI findings in progressive multifocal leukoencephalopathy (PML) associated to rituximab and natalizumab treatments and HIV infection. Materials and methods: In this retrospective, multicentric study, we analyzed brain MRI exams from 72 patients diagnosed with definite PML: 32 after natalizumab treatment, 20 after rituximab treatment, and 20 HIV patients. We compared T2- or FLAIR-weighted images, diffusion-weighted images, T2*-weighted images, and contrast enhancement features, as well as lesion distribution, especially gray matter involvement. Results: The three PML entities affect U-fibers associated with low signal intensities on T2*-weighted sequences. Natalizumab-associated PML showed a punctuate microcystic appearance in or in the vicinity of the main PML lesions, a potential involvement of the cortex, and contrast enhancement. HIV and rituximab-associated PML showed only mild contrast enhancement, punctuate appearance, and cortical involvement. The CD4/CD8 ratio showed a trend to be higher in the natalizumab group, possibly mirroring a more efficient immune response. Conclusion: Imaging features of rituximab-associated PML are different from those of natalizumab-associated PML and are closer to those observed in HIV-associated PML.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/05/2021
• Auteurs : Elisabeth ChenNicolas NesselerRaphaël P MartinsCéline GoéminneAndré VincentelliClément DelmasJean PorterieKarine NubretMathieu PernotMichel KindoTam Hoang MinhPhilippe GaudardPhilippe RouvièreMagali MichelThomas SénageAude BoignardOlivier ChavanonConstance VerdonkMarylou ParaEdeline PelcéVlad GariboldiMatteo PozziGuillaume CoutancePierre-Yves LitzlerFrédéric AnselmeKatrien BlanchartGerard BabatasiFabien GarnierMarie BielefeldCostin RaduNicolas LelloucheThierry BourguignonThibaud GenetRomain EschalierNicolas D’ostrevyMarie-Cécile BoriesPierre BaudinaudFabrice VanhuyseHugues BlangyChristophe LeclercqErwan FlécherVincent Galand
• Organismes : Laboratoire Traitement du Signal et de l'Image Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Laboratoire Traitement du Signal et de l'Image Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Laboratoire Traitement du Signal et de l'Image Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Institut Coeur Poumon [CHU Lille] Institut Coeur Poumon [CHU Lille] Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Toulouse Institut de rythmologie et modélisation cardiaque [Pessac] Institut de rythmologie et modélisation cardiaque [Pessac] Hôpitaux Universitaires de Strasbourg Hôpitaux Universitaires de Strasbourg Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Hôpital Michallon Hôpital Michallon AP-HP - Hôpital Bichat - Claude Bernard [Paris] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Hôpital de la Timone [CHU - APHM] Hôpital de la Timone [CHU - APHM] Hôpital Louis Pradel [CHU - HCL] Hôpital Louis Pradel [CHU - HCL] Hôpital Charles Nicolle [Rouen] Hôpital Charles Nicolle [Rouen] CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand CHU Henri Mondor [Créteil] CHU Henri Mondor [Créteil] Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Régional Universitaire de Tours CHU Clermont-Ferrand CHU Clermont-Ferrand Hôpital Européen Georges Pompidou [APHP] Hôpital Européen Georges Pompidou [APHP] Centre Hospitalier Régional Universitaire de Nancy Centre Hospitalier Régional Universitaire de Nancy Laboratoire Traitement du Signal et de l'Image Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Laboratoire Traitement du Signal et de l'Image Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Laboratoire Traitement du Signal et de l'Image
• Publié dans American Journal of Cardiology le 22/10/2020

---

Résumé : LVAD implantation in patients with a recently diagnosed cardiomyopathy has been poorly investigated. This work aims at describing the characteristics and outcomes of patients receiving a LVAD within 30 days following the diagnosis of cardiomyopathy. Patients from the ASSIST-ICD study was divided into recently and remotely diagnosed cardiomyopathy based on the time from initial diagnosis of cardiomyopathy to LVAD implantation using the cut point of 30 days. The primary end point of the study was all-cause mortality at 30-day and during follow-up. A total of 652 patients were included and followed during a median time of 9.1 (2.5 to 22.1) months. In this population, 117 (17.9%) had a recently diagnosed cardiomyopathy and had LVAD implantation after a median time of 15.0 (9.0 to 24.0) days following the diagnosis. This group of patients was significantly younger, with more ischemic cardiomyopathy, more sudden cardiac arrest (SCA) events at the time of the diagnosis and were more likely to receive temporary mechanical support before LVAD compared with the remotely diagnosed group. Postoperative in-hospital survival was similar in groups, but recently diagnosed patients had a better long-term survival after hospital discharge. SCA before LVAD and any cardiac surgery combined with LVAD implantation were identified as 2 independent predictors of postoperative mortality in recently diagnosed patients. In conclusion, rescue LVAD implantation for recently diagnosed severe cardiomyopathy is common in clinical practice. Such patients experience a relatively low postoperative mortality and have a better long-term survival compared with remotely diagnosed patients.

---

Fichiers liés : Chen et al. - 2021 - Comparison of Outcomes and Mortality in Patients H.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/05/2021
• Auteurs : Tae-Hwi Schwantes-AnRebecca DarlayPhilippe MathurinSteven MassonSuthat LiangpunsakulSebastian MuellerGuruprasad P. AithalFlorian EyerDermot GleesonAndrew ThompsonBeat MuellhauptFelix StickelMichael SoykaDavid GoldmanTiebing LiangLawrence LumengMunir PirmohamedBertrand NalpasJean-Marc JacquetRomain MoirandPierre NahonSylvie S. NaveauPascal PerneyGreg BotwinPaul S HaberHelmut K. SeitzChristopher P. DayTatiana M ForoudAnn K. DalyHeather J. CordellJohn B WhitfieldTimothy R MorganDevanshi Seth
• Organismes : Indiana University System Newcastle University [Newcastle] Centre Hospitalier Régional Universitaire [CHU Lille] Newcastle University [Newcastle] Indiana University System University of Heidelberg, Medical Faculty University of Nottingham, UK Technische Universität Munchen = Technical University Munich = Université Technique de Munich Royal Hallamshire Hospital University of Liverpool University hospital of Zurich [Zurich] University hospital of Zurich [Zurich] Klinikum der Universität [München] Indiana University System Indiana University System University of Liverpool Service Addictologie [CHU Nîmes] Service Addictologie [CHU Nîmes] Nutrition, Métabolismes et Cancer Hôpital Jean Verdier [AP-HP] AP-HP - Hôpital Antoine Béclère [Clamart] Service Addictologie [CHU Nîmes] Veterans Affairs Long Beach Healthcare System NSW Government The University of Sydney University of Heidelberg, Medical Faculty Newcastle University [Newcastle] Indiana University System Newcastle University [Newcastle] Newcastle University [Newcastle] QIMR Berghofer Medical Research Institute Veterans Affairs Long Beach Healthcare System NSW Government The University of Sydney
• Publié dans Hepatology le 30/10/2020

---

Résumé : Background and aims - Only a minority of heavy drinkers progress to alcohol-associated cirrhosis (ALC). The aim of this study was to identify common genetic variants that underlie risk for ALC. Approach and results - We analyzed data from 1,128 subjects of European ancestry with ALC and 614 heavy-drinking subjects without known liver disease from Australia, the United States, the United Kingdom, and three countries in Europe. A genome-wide association study (GWAS) was performed, adjusting for principal components and clinical covariates (alcohol use, age, sex, body mass index, and diabetes). We validated our GWAS findings using UK Biobank. We then performed a meta-analysis combining data from our study, the UK Biobank, and a previously published GWAS. Our GWAS found genome-wide significant risk association of rs738409 in patatin-like phospholipase domain containing 3 (PNPLA3) (odds ratio [OR] = 2.19 [G allele], P = 4.93 × 10 ) and rs4607179 near HSD17B13 (OR = 0.57 [C allele], P = 1.09 × 10 ) with ALC. Conditional analysis accounting for the PNPLA3 and HSD17B13 loci identified a protective association at rs374702773 in Fas-associated factor family member 2 (FAF2) (OR = 0.61 [del(T) allele], P = 2.56 × 10 ) for ALC. This association was replicated in the UK Biobank using conditional analysis (OR = 0.79, P = 0.001). Meta-analysis (without conditioning) confirmed genome-wide significance for the identified FAF2 locus as well as PNPLA3 and HSD17B13. Two other previously known loci (SERPINA1 and SUGP1/TM6SF2) were also genome-wide significant in the meta-analysis. GeneOntology pathway analysis identified lipid droplets as the target for several identified genes. In conclusion, our GWAS identified a locus at FAF2 associated with reduced risk of ALC among heavy drinkers. Like the PNPLA3 and HSD17B13 gene products, the FAF2 product has been localized to fat droplets in hepatocytes. Conclusions - Our genetic findings implicate lipid droplets in the biological pathway(s) underlying ALC.

---

Fichiers liés : Schwantes‐An et al-2020-Genome-wide association study and meta-analysis on alcohol-related liver.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/05/2021
• Auteurs : Yuanwei QinXiangming XiaoWigneron J.-P.Philippe CiaisMartin BrandtSassan S SaatchiXiaojun LiSean CrowellXiaocui WuRussell DoughtyYao ZhangFang LiuStephen SitchBerrien Moore
• Organismes : University of Oklahoma University of Oklahoma Interactions Sol Plante Atmosphère Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] ICOS-ATC University of Copenhagen = Københavns Universitet Interactions Sol Plante Atmosphère Interactions Sol Plante Atmosphère University of Oklahoma University of Oklahoma University of Oklahoma Lawrence Berkeley National Laboratory [Berkeley] Chinese Academy of Sciences [Beijing] University of Exeter University of Oklahoma
• Publié dans Nature Climate Change le 30/10/2020

---

Résumé : Spatial–temporal dynamics of aboveground biomass (AGB) and forest area affect the carbon cycle, climate and biodiversity in the Brazilian Amazon. Here we investigate interannual changes in AGB and forest area by analysing satellite-based annual AGB and forest area datasets. We found that the gross forest area loss was larger in 2019 than in 2015, possibly due to recent loosening of forest protection policies. However, the net AGB loss was three times smaller in 2019 than in 2015. During 2010–2019, the Brazilian Amazon had a cumulative gross loss of 4.45 Pg C against a gross gain of 3.78 Pg C, resulting in a net AGB loss of 0.67 Pg C. Forest degradation (73%) contributed three times more to the gross AGB loss than deforestation (27%), given that the areal extent of degradation exceeds that of deforestation. This indicates that forest degradation has become the largest process driving carbon loss and should become a higher policy priority.

---

Fichiers liés : s41558-021-01026-5.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/05/2021
• Auteurs : Ronan RousselPatrice DarmonMatthieu PichelinThomas GoronflotYawa AboulekaLeila Ait BachirIngrid AllixDeborah AncelleSara BarraudLyse BordierAurélie CarlierNicolas ChevalierChristine Coffin‐boutreuxEmmanuel CossonAnne DorangeOlivier DupuyPierre FontaineBénédicte FremyFlorence GaltierNatacha GermainAnne‐marie GuedjEtienne LargerStéphanie Laugier‐robiolleBruno LaviolleLisa LudwigArnaud MonierNathanaëlle MontanierPhilippe MoulinIsabelle MouraGaëtan PrevostYves ReznikNadia SabbahPierre-Jean SaulnierPierre SerusclatCamille VatierMatthieu WargnySamy HadjadjPierre GourdyBertrand Cariou
• Organismes : Centre de Recherche des Cordeliers Service d'endocrinologie, diabétologie et nutrition [CHU Bichat] Aix Marseille Université Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research ITX - unité de recherche de l'institut du thorax Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre d’Investigation Clinique de Nantes Centre de Recherche des Cordeliers Service d'endocrinologie, diabétologie et nutrition [CHU Bichat] CHU d'Angers [Département Urgences] Centre Hospitalier Universitaire d'Angers Groupe Hospitalier du Havre Hôpital Jacques Monod (MONTIVILLIERS) Centre de Recherche en Sciences et Technologies de l'Information et de la Communication - EA 3804 Hôpital d'Instruction des Armées Begin [Saint-Mandé, France] Centre de Recherche des Cordeliers Service d'endocrinologie, diabétologie et nutrition [CHU Bichat] Centre méditerranéen de médecine moléculaire Unité de Recherche en Epidémiologie Nutritionnelle Centre Hospitalier Le Mans (CH Le Mans) Centre hospitalier Saint-Joseph [Paris] Hôpital Claude Huriez [Lille] CIC Montpellier Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Centre Hospitalier Universitaire de Nîmes Service de diabétologie [CHU Cochin] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre Hospitalier Universitaire de Nancy Hôpitaux de Chartres [Chartres] Cardiovasculaire, métabolisme, diabétologie et nutrition Service d'endocrinologie, diabétologie et maladies métaboliques [Rouen] Différenciation et communication neuronale et neuroendocrine Service Endocrinologie - Diabétologie [CHU Caen] Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française] CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Centre de Recherche Saint-Antoine ITX - unité de recherche de l'institut du thorax Centre Hospitalier Universitaire de Nantes = Nantes University Hospital ITX - unité de recherche de l'institut du thorax Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Institut des Maladies Métaboliques et Cardiovasculaires ITX - unité de recherche de l'institut du thorax Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
• Publié dans Diabetes, Obesity and Metabolism le 01/11/2020

---

Résumé : Aim: To investigate the association between routine use of dipeptidyl peptidase-4 (DPP-4) inhibitors and the severity of coronavirus disease 2019 (COVID-19) infection in patient with type 2 diabetes in a large multicentric study. Materials and Methods: This study was a secondary analysis of the CORONADO study on 2449 patients with type 2 diabetes (T2D) hospitalized for COVID-19 in 68 French centres. The composite primary endpoint combined tracheal intubation for mechanical ventilation and death within 7 days of admission. Stabilized weights were computed for patients based on propensity score (DPP-4 inhibitors users vs. non-users) and were used in multivariable logistic regression models to estimate the average treatment effect in the treated as inverse probability of treatment weighting (IPTW). Results: Five hundred and ninety-six participants were under DPP-4 inhibitors before admission to hospital (24.3%). The primary outcome occurred at similar rates in users and non-users of DPP-4 inhibitors (27.7% vs. 28.6%; p = .68). In propensity analysis, the IPTW-adjusted models showed no significant association between the use of DPP-4 inhibitors and the primary outcome by Day 7 (OR [95% CI]: 0.95 [0.77-1.17]) or Day 28 (OR [95% CI]: 0.96 [0.78-1.17]). Similar neutral findings were found between use of DPP-4 inhibitors and the risk of tracheal intubation and death. Conclusions: These data support the safety of DPP-4 inhibitors for diabetes management during the COVID-19 pandemic and they should not be discontinued.

---

Fichiers liés : Roussel et al-2021-Use of Dipeptidyl Peptidase-4 inhibitors and prognosis of COVID-19 in.pdf

---

Source